Clicky

Depression

Mother speaks out about handling postpartum depression after pregnancy

One mother is sharing the struggle of her story postpartum depression story and who she was able to get the support she needed. We spoke with the mother about her journey. One mother from Edinboro spoke about how she felt with having postpartum depression after having two pregnancies. For Amanda Carter, during her first pregnancy […]

Mother speaks out about handling postpartum depression after pregnancy Read More »

America’s top psychiatrist shares research on improving mental health during the pandemic

WAUSAU, Wis. (WSAW) – During this historically stressful time, it’s not surprising that the incidence of depression has tripled and that doctors have been working overtime to help people manage critical emotional problems. Now, as the nation struggles with the pandemic, a new book has just been released by #1 New York Times bestselling author Dr. Daniel Amen,

America’s top psychiatrist shares research on improving mental health during the pandemic Read More »

[Full text] Use of the Taiwanese Depression Questionnaire and the AD8 Qu

Background Major depressive disorder (MDD) is an important disease with wide distribution across age groups and the world, with substantial severity that can threaten individuals’ socioeconomic behavior. MDD prevalence is 16.2% overall and 6.6% annually.1 Effectively detecting depression has become a crucial goal in public mental health. However, emotional expression patterns vary on the basis

[Full text] Use of the Taiwanese Depression Questionnaire and the AD8 Qu Read More »

Selective Serotonin Reuptake Inhibitors, Phenylpiperazine, Tetracyclic, Tricyclic, Atypical, CNS Stimulant, MAO Inhibitors, Serotonin-Norepinephrine

DUBLIN, March 8, 2021 /PRNewswire/ — The “US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The complete research report is divided into several sections focusing on the approaches followed for sales and marketing, research and development, specific clinical trials and tailored capabilities of the major bio-pharmaceutical companies

Selective Serotonin Reuptake Inhibitors, Phenylpiperazine, Tetracyclic, Tricyclic, Atypical, CNS Stimulant, MAO Inhibitors, Serotonin-Norepinephrine Read More »

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

Sandusky, Ohio–(Newsfile Corp. – March 8, 2021) – PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The company recently announced plans to produce a variety of nutraceuticals for additional applications

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market Read More »

Selective Serotonin Reuptake Inhibitors, Phenylpiperazine, Tetracyclic, Tricyclic, Atypical, CNS Stimulant, MAO Inhibitors, Serotonin-Norepinephrine

DUBLIN, March 8, 2021 /PRNewswire/ — The “US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026” report has been added to ResearchAndMarkets.com’s offering. Research and Markets Logo The complete research report is divided into several sections focusing on the approaches followed for sales and marketing, research and development, specific clinical trials and tailored capabilities of

Selective Serotonin Reuptake Inhibitors, Phenylpiperazine, Tetracyclic, Tricyclic, Atypical, CNS Stimulant, MAO Inhibitors, Serotonin-Norepinephrine Read More »